Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: A randomised, 52-week, open-label, safety study

BMC Neurology

Volumn 16, Issue 1, 2016, Pages

  Vinik, Aaron I ^a   Perrot, Serge ^b   Vinik, Etta J ^a   Pazdera, Ladislav ^c   Jacobs, Hélène ^d   Stoker, Malcolm ^d   Long, Stephen K ^d,h   Snijder, Robert J ^d   van der Stoep, Marjolijne ^d   Ortega, Enrique ^e   Katz, Nathaniel ^f,g  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b HÔTEL DIEU   (France)

^c Vestra Clinics Dedicated Research Clinics   (Czech Republic)

^d Astellas Pharma Global Development   (Netherlands)

^e HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^f Analgesic Solutions   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h SYNEOS HEALTH   (United States)

Author keywords

Capsaicin 8 patch; Norfolk QOL DN; Painful diabetic peripheral neuropathy; TPRV1; UENS

Indexed keywords

CAPSAICIN; AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS;

ADULT; ANGINA PECTORIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE REACTION; ARTICLE; BURNING SENSATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; FEMALE; HEALTH CARE QUALITY; HUMAN; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; MULTICENTER STUDY; MUSCLE SPASM; NEURALGIA; OPEN STUDY; PAIN; PAINFUL DIABETIC PERIPHERAL NEUROPATHY; PERCEPTION; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CARCINOMA; REFLEX; REPEATED DRUG DOSE; SIDE EFFECT; TRANSDERMAL PATCH; AGED; CLINICAL TRIAL; COMPLICATION; CUTANEOUS DRUG ADMINISTRATION; DIABETIC NEUROPATHIES; MIDDLE AGED; OUTCOME ASSESSMENT;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; CAPSAICIN; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; OUTCOME ASSESSMENT (HEALTH CARE); SENSORY SYSTEM AGENTS; STANDARD OF CARE;

EID: 85002572430     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-016-0752-7     Document Type: Article

References (23)

1. Jensen MP, Chodroff MJ, Dworkin RH, et al. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178-82.
2. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complicat. 2006;20:26-33.
3. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-4.
4. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-22.
5. Huizinga MM, Peltier A. Painful diabetic neuropathy: a management-centered review. Clin Diabetes. 2007;25:6-15.
6. Jensen TS, Backonja MM, Hernández Jiménez S, et al. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res. 2006;3:108-19.
7. Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16:E705-14.
8. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128:169-79.
9. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-73.
10. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490-502.
11. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106-12.
12. Brown S, Simpson DM, Moyle G, et al. NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials. AIDS Res Ther. 2013;10:5.
13. Haanpää M, Cruccu G, Nurmikko T, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016;20:316-28.
14. Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12:99-101.
15. Simpson DM, Brown S, Tobias J, for the NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305-13.
16. Simpson DM, Robinson-Papp J, Van J, Stoker M, et al. Capsaicin 8% Patch in Painful Diabetic Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Study. J Pain. 2016. [Epub ahead of print].
17. Vinik EJ, Hayes RP, Oglesby A, et al. The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther. 2005;7:497-508.
18. Astellas Pharma Ltd. QUTENZA™ 179 mg cutaneous patch SPC (2015). Available at https://www.medicines.org.uk/emc/medicine/23156. Accessed 4 Apr 2016.
19. Boyd A, Casselini C, Vinik E, Vinik A. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol. 2011;5:714-22.
20. Singleton J, Bixby B, Russel JW, et al. The Utah early neuropathy scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. 2008;13:218-27.
21. Casellini CM, Barlow PM, Rice AL, Casey M, Simmons K, Pittenger G, et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care. 2007;30:896-902.
22. Maier C, Baron R, Tölle TR, et al. Quantitative sensory testing in the German research network on neuropathic pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain. 2010;150:439-50.
23. Backonja MM, Attal N, Baron R, et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain. 2013;154:1807-19.